Status:
COMPLETED
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) Study
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Conditions:
Prostate Cancer
Metastatic Hormone-sensitive Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
The purpose of this study is to quantify and publish participants' relative preferences for outcomes of chemotherapy and novel oral hormonal agents when added to androgen deprivation therapy (ADT) for...
Detailed Description
The study will develop and administer a discrete-choice experiment (DCE) to quantify tradeoff preferences of participants with mHSPC and locally-advanced prostate cancer in various countries. Data/sur...
Eligibility Criteria
Inclusion
- For interviews (attribute prioritization and pretest interviews)
- Diagnosis of mHSPC with or without previous experience with ADT
- Able to read and understand the survey language
- Able to provide informed consent For online survey
- Diagnosis of mHSPC or locally-advanced prostate cancer with or without previous experience with ADT
- Able to read and understand the survey language
- Able to provide informed consent
Exclusion
- Not applicable
Key Trial Info
Start Date :
September 3 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 11 2022
Estimated Enrollment :
1020 Patients enrolled
Trial Details
Trial ID
NCT05381311
Start Date
September 3 2021
End Date
December 11 2022
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Clinical Research Institute
Durham, North Carolina, United States, 27701